
    
      PRIMARY OBJECTIVES:

      I. To assess whether providing a patient with "5+5" dosing in a 2 step matched related donor
      hematopoietic stem cell transplantation (HSCT) increases the percentage of patients who
      achieve full donor chimerism earlier as defined by 98% or greater donor T cell chimerism at
      28 days post HSCT (d+28).

      SECONDARY OBJECTIVES:

      I. To assess day (d) +90 chimerism in patients receiving "5+5" dosing. II. To assess post
      HSCT relapse rates in patients receiving "5+5" dosing. III. To assess rates of grade II-IV
      graft versus host disease (GVHD) in patients receiving "5+5" dosing.

      IV. To assess treatment-related mortality (TRM) in patients receiving "5+5" dosing.
    
  